|
B-Cell Lymphomas – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 326 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H1 2012', provides an overview of the B-Cell Lymphomas therapeutic pipeline. This report provides information on the therape.....
Introduction Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H1 2012', provides an overview of the B-Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. 'B-Cell Lymphomas - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for B-Cell Lymphomas. - A review of the B-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the B-Cell Lymphomas pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for B-Cell Lymphomas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding B-Cell Lymphomas pipeline depth and focus of B-Cell Lymphomas therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 B-Cell Lymphomas Overview 12 Therapeutics Development 13 An Overview of Pipeline Products for B-Cell Lymphomas 13 B-Cell Lymphomas Therapeutics under Development by Companies 15 B-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 22 Late Stage Products 34 Comparative Analysis 34 Mid Clinical Stage Products 35 Comparative Analysis 35 Early Clinical Stage Products 36 Comparative Analysis 36 Discovery and Pre-Clinical Stage Products 37 Comparative Analysis 37 B-Cell Lymphomas Therapeutics – Products under Development by Companies 38 B-Cell Lymphomas Therapeutics – Products under Investigation by Universities/Institutes 48 Companies Involved in B-Cell Lymphomas Therapeutics Development 74 Bristol-Myers Squibb Company 74 Genzyme Corporation 75 Johnson & Johnson 76 F. Hoffmann-La Roche Ltd. 77 Kyowa Hakko Kirin Co., Ltd. 78 Abbott Laboratories 79 Amgen Inc. 80 Sanofi-Aventis 81 AstraZeneca PLC 82 Eli Lilly and Company 83 GlaxoSmithKline plc 84 Seattle Genetics, Inc. 85 Genentech, Inc. 86 Antigenics, Inc. 87 MMR Information Systems, Inc. 88 MedImmune LLC 89 Gilead Sciences, Inc. 90 Merck & Co., Inc. 91 Lentigen Corporation 92 Micromet, Inc. 93 Takeda Pharmaceutical Company Limited 94 ZIOPHARM Oncology, Inc. 95 Millennium Pharmaceuticals, Inc. 96 Novartis AG 97 Astellas Pharma Inc. 98 BioMarin Pharmaceutical Inc. 99 Cephalon, Inc. 100 Glenmark Pharmaceuticals Ltd. 101 ImmunoGen, Inc. 102 Pfizer Inc. 103 Sunesis Pharmaceuticals, Inc. 104 SuperGen, Inc. 105 Teva Pharmaceutical Industries Limited 106 Cell Therapeutics, Inc. 107 Genmab A/S 108 Celgene Corporation 109 Onyx Pharmaceuticals, Inc. 110 Bayer AG 111 Incyte Corporation 112 Celldex Therapeutics, Inc. 113 AEterna Zentaris Inc. 114 IMMUNOMEDICS, INC 115 InNexus Biotechnology Inc. 116 MethylGene Inc 117 Curis, Inc. 118 Accentia Biopharmaceuticals, Inc. 119 Allos Therapeutics, Inc 120 Telik, Inc. 121 Pharmacyclics, Inc. 122 MorphoSys AG 123 Green Cross Corporation 124 Innate Pharma SA 125 Piramal Life Sciences Limited 126 SymBio Pharmaceuticals Limited 127 Chipscreen Biosciences Ltd 128 Memgen, LLC. 129 PanGenetics B.V. 130 Biolex Therapeutics, Inc. 131 Ascenta Therapeutics, Inc. 132 Provenance Biopharmaceuticals Corp. 133 Celentyx Ltd. 134 Fresenius Biotech GmbH 135 Semafore Pharmaceuticals, Inc. 136 S*BIO Pte Ltd 137 Onconova Therapeutics, Inc 138 Immune System Therapeutics Ltd. 139 Intellikine, Inc. 140 Xencor, Inc. 141 VentiRx Pharmaceuticals, Inc. 142 CureTech Ltd. 143 Cylene Pharmaceuticals, Inc. 144 Dynamix Pharmaceuticals Ltd. 145 Zenyaku Kogyo Co., Ltd. 146 Probiomed S.A. de C.V. 147 PharmaTech International, Inc. 148 B-Cell Lymphomas – Therapeutics Assessment 149 Assessment by Monotherapy Products 149 Assessment by Combination Products 150 Assessment by Route of Administration 151 Assessment by Molecule Type 154 Drug Profiles 157 RG7159 - Drug Profile 157 Enzastaurin - Drug Profile 158 MAbThera - Drug Profile 160 BiovaxID - Drug Profile 162 Velcade - Drug Profile 164 Epratuzumab - Drug Profile 165 Rituximab - Drug Profile 166 Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 167 Bendamustine + Rituximab - Drug Profile 169 Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile 170 Rituximab + Chlorambucil - Drug Profile 172 Rituximab - Drug Profile 173 Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile 174 Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile 176 Fludarabine Phosphate - Drug Profile 178 Chlorambucil For Follicular lymphoma - Drug Profile 179 Velcade + Rituximab - Drug Profile 180 Treanda + Rituxan - Drug Profile 182 Revlimid - Drug Profile 184 Arzerra + Bendamustine - Drug Profile 186 Ofatumumab + DHAP - Drug Profile 188 Pixantrone + Rituximab - Drug Profile 190 Avastin + R-CHOP - Drug Profile 191 RG7159 + CHOP - Drug Profile 193 Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 196 Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 198 Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 200 EPOCH + Rituximab - Drug Profile 202 Rituximab - Drug Profile 204 Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 205 Rituximab + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 208 Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile 210 Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile 212 VELCADE-R-CAP - Drug Profile 214 Rituximab + Cyclophosphamide + Fludarabine - Drug Profile 216 Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Cisplatin + Dexamethasone + Cytarabine + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 217 R-CHOP + Radiation Therapy - Drug Profile 219 Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 221 Rituximab - Drug Profile 223 Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile 225 Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Iodine-131 Tositumomab - Drug Profile 227 Fludarabine - Drug Profile 229 FavId + Sargramostim + Rituximab - Drug Profile 230 Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile 232 Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 234 Carmustine + Cyclophosphamide + Cytarabine + Etoposide + Melphalan + Autologous Stem Cell Transplantation + Rituximab - Drug Profile 236 R-CHOP14 + Neulasta - Drug Profile 238 Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone - Drug Profile 240 Rituxan + FavId + GM-CSF - Drug Profile 242 DHAP + Rituximab - Drug Profile 243 ICE + RITUXIMAB - Drug Profile 244 Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 245 Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile 247 Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 250 R-FM - Drug Profile 253 R-CVP - Drug Profile 254 Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile 256 R-CHOP14 + Darbepoetin Alfa - Drug Profile 258 Rituximab-HDS - Drug Profile 260 Bleomycin Sulfate + Rituximab + CHOP Regimen + EPOCH Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Methotrexate + Mitoxantrone Hydrochloride + Prednisolone + Prednisone + Vincristine Sulfate - Drug Profile 261 Filgrastim + Recombinant Interferon Alfa + Carmustine + Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Melphalan + Radiation Therapy + Peripheral Blood Stem Cell Transplantation - Drug Profile 265 Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile 268 Lenalidomide - Drug Profile 271 R-CHOP - Drug Profile 272 Revlimid + Rituxan - Drug Profile 275 Biosimilar Rituximab - Drug Profile 276 PBO-326 - Drug Profile 277 Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile 278 B-Cell Lymphomas Therapeutics – Drug Profile Updates 280 B-Cell Lymphomas Therapeutics – Discontinued Products 293 B-Cell Lymphomas Therapeutics - Dormant Products 297 B-Cell Lymphomas – Product Development Milestones 308 Featured News & Press Releases 308 Appendix 320 Methodology 320 Expert Panel Validation 321 Contact Us 321 Disclaimer 321 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for B-Cell Lymphomas, H1 2012 18 Products under Development for B-Cell Lymphomas – Comparative Analysis, H1 2012 19 Number of Products under Development by Companies, H1 2012 21 Number of Products under Development by Companies, H1 2012 (Contd..1) 22 Number of Products under Development by Companies, H1 2012 (Contd..2) 23 Number of Products under Development by Companies, H1 2012 (Contd..3) 24 Number of Products under Development by Companies, H1 2012 (Contd..4) 25 Number of Products under Development by Companies, H1 2012 (Contd..5) 26 Number of Products under Investigation by Universities/Institutes, H1 2012 28 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 29 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 30 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 31 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 32 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 33 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 34 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 35 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 36 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 37 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 38 Comparative Analysis by Late Stage Development, H1 2012 39 Comparative Analysis by Mid Clinical Stage Development, H1 2012 40 Comparative Analysis by Early Clinical Stage Development, H1 2012 41 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 42 Products under Development by Companies, H1 2012 43 Products under Development by Companies, H1 2012 (Contd..1) 44 Products under Development by Companies, H1 2012 (Contd..2) 45 Products under Development by Companies, H1 2012 (Contd..3) 46 Products under Development by Companies, H1 2012 (Contd..4) 47 Products under Development by Companies, H1 2012 (Contd..5) 48 Products under Development by Companies, H1 2012 (Contd..6) 49 Products under Development by Companies, H1 2012 (Contd..7) 50 Products under Development by Companies, H1 2012 (Contd..8) 51 Products under Development by Companies, H1 2012 (Contd..9) 52 Products under Investigation by Universities/Institutes, H1 2012 53 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 54 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 55 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 56 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 57 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 58 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 59 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 60 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 61 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 62 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 63 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 64 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 65 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 66 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 67 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 68 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 69 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 70 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 71 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 72 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 73 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 74 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 75 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 76 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 77 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 78 Bristol-Myers Squibb Company, H1 2012 79 Genzyme Corporation, H1 2012 80 Johnson & Johnson, H1 2012 81 F. Hoffmann-La Roche Ltd., H1 2012 82 Kyowa Hakko Kirin Co., Ltd., H1 2012 83 Abbott Laboratories, H1 2012 84 Amgen Inc., H1 2012 85 Sanofi-Aventis, H1 2012 86 AstraZeneca PLC, H1 2012 87 Eli Lilly and Company, H1 2012 88 GlaxoSmithKline plc, H1 2012 89 Seattle Genetics, Inc., H1 2012 90 Genentech, Inc., H1 2012 91 Antigenics, Inc., H1 2012 92 MMR Information Systems, Inc., H1 2012 93 MedImmune LLC, H1 2012 94 Gilead Sciences, Inc., H1 2012 95 Merck & Co., Inc., H1 2012 96 Lentigen Corporation, H1 2012 97 Micromet, Inc., H1 2012 98 Takeda Pharmaceutical Company Limited, H1 2012 99 ZIOPHARM Oncology, Inc., H1 2012 100 Millennium Pharmaceuticals, Inc., H1 2012 101 Novartis AG, H1 2012 102 Astellas Pharma Inc., H1 2012 103 BioMarin Pharmaceutical Inc., H1 2012 104 Cephalon, Inc., H1 2012 105 Glenmark Pharmaceuticals Ltd., H1 2012 106 ImmunoGen, Inc., H1 2012 107 Pfizer Inc., H1 2012 108 Sunesis Pharmaceuticals, Inc., H1 2012 109 SuperGen, Inc., H1 2012 110 Teva Pharmaceutical Industries Limited, H1 2012 111 Cell Therapeutics, Inc., H1 2012 112 Genmab A/S, H1 2012 113 Celgene Corporation, H1 2012 114 Onyx Pharmaceuticals, Inc., H1 2012 115 Bayer AG, H1 2012 116 Incyte Corporation, H1 2012 117 Celldex Therapeutics, Inc., H1 2012 118 AEterna Zentaris Inc., H1 2012 119 IMMUNOMEDICS, INC, H1 2012 120 InNexus Biotechnology Inc., H1 2012 121 MethylGene Inc, H1 2012 122 Curis, Inc., H1 2012 123 Accentia Biopharmaceuticals, Inc., H1 2012 124 Allos Therapeutics, Inc, H1 2012 125 Telik, Inc., H1 2012 126 Pharmacyclics, Inc., H1 2012 127 MorphoSys AG, H1 2012 128 Green Cross Corporation, H1 2012 129 Innate Pharma SA, H1 2012 130 Piramal Life Sciences Limited, H1 2012 131 SymBio Pharmaceuticals Limited, H1 2012 132 Chipscreen Biosciences Ltd, H1 2012 133 Memgen, LLC., H1 2012 134 PanGenetics B.V., H1 2012 135 Biolex Therapeutics, Inc., H1 2012 136 Ascenta Therapeutics, Inc., H1 2012 137 Provenance Biopharmaceuticals Corp., H1 2012 138 Celentyx Ltd., H1 2012 139 Fresenius Biotech GmbH, H1 2012 140 Semafore Pharmaceuticals, Inc., H1 2012 141 S*BIO Pte Ltd, H1 2012 142 Onconova Therapeutics, Inc, H1 2012 143 Immune System Therapeutics Ltd., H1 2012 144 Intellikine, Inc., H1 2012 145 Xencor, Inc., H1 2012 146 VentiRx Pharmaceuticals, Inc., H1 2012 147 CureTech Ltd., H1 2012 148 Cylene Pharmaceuticals, Inc., H1 2012 149 Dynamix Pharmaceuticals Ltd., H1 2012 150 Zenyaku Kogyo Co., Ltd., H1 2012 151 Probiomed S.A. de C.V., H1 2012 152 PharmaTech International, Inc., H1 2012 153 Assessment by Monotherapy Products, H1 2012 154 Assessment by Combination Products, H1 2012 155 Assessment by Stage and Route of Administration, H1 2012 158 Assessment by Molecule Type, H1 2012 161 B-Cell Lymphomas Therapeutics – Drug Profile Updates 285 B-Cell Lymphomas Therapeutics – Discontinued Products 298 B-Cell Lymphomas Therapeutics – Discontinued Products (Contd..1) 299 B-Cell Lymphomas Therapeutics – Discontinued Products (Contd..2) 300 B-Cell Lymphomas Therapeutics – Discontinued Products (Contd..3) 301 B-Cell Lymphomas Therapeutics – Dormant Products 302 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..1) 303 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..2) 304 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..3) 305 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..4) 306 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..5) 307 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..6) 308 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..7) 309 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..8) 310 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..9) 311 B-Cell Lymphomas Therapeutics – Dormant Products (Contd..10) 312 List of Figures Number of Products under Development for B-Cell Lymphomas, H1 2012 18 Products under Development for B-Cell Lymphomas – Comparative Analysis, H1 2012 19 Products under Development by Companies, H1 2012 20 Products under Investigation by Universities/Institutes, H1 2012 27 Late Stage Products, H1 2012 39 Mid Clinical Stage Products, H1 2012 40 Early Clinical Stage Products, H1 2012 41 Discovery and Pre-Clinical Stage Products, H1 2012 42 Assessment by Monotherapy Products, H1 2012 154 Assessment by Combination Products, H1 2012 155 Assessment by Route of Administration, H1 2012 156 Assessment by Stage and Route of Administration, H1 2012 157 Assessment by Molecule Type, H1 2012 159 Assessment by Stage and Molecule Type, H1 2012 160 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
